P154 BEROTRALSTAT IMPROVES PATIENT-REPORTED QUALITY OF LIFE THROUGH 48 WEEKS IN THE PHASE 3 APEX-2 TRIALD. Johnston,A. Banerji,M. Riedl,D. Soteres, J. Bernstein,J. Best, H. Iocca,S. Murray,W. LumryAnnals of Allergy, Asthma & Immunology(2020)引用 3|浏览40暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要